Chronic depression: Classification and therapeutic strategies;Chronische depression: Klassifikation und behandlungsstrategien

Zeitschrift fur Psychiatrie, Psychologie und Psychotherapie

Volumn 57, Issue 4, 2009, Pages 245-251

  Mikoteit, Thorsten ^a   Hatzinger, Martin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chronic depression; Classifications; Combination treatment; Pharmacotherapy; Predictive variables

Indexed keywords

ANTIDEPRESSANT AGENT;

CHRONIC DISEASE; DEPRESSION; DISEASE CLASSIFICATION; HUMAN; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW;

EID: 69449084376     PISSN: 16614747     EISSN: None     Source Type: Journal    
DOI: 10.1024/1661-4747.57.4.245     Document Type: Review

References (54)

1. Adli, M., Baethge, C., Heinz, A., Langlitz, N.&Bauer,M. (2005). Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European Archives of Psychiatry and Clinical Neuroscience, 255, 387-400.
2. Amore, M., Jori,M.C. & AMISERT Investigators. (2001). Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. International Clinical Psychopharmacology, 16, 317-324. (Pubitemid 33030046)
3. Angst, J., Sellaro, R., Stassen, H. H. & Gamma, A. (2005). Diagnostic conversion fromdepression to bipolar disorders: Results of a long-term prospective study of hospital admissions. Journal of Affective Disorders, 84, 149-157. (Pubitemid 40222496)
4. Arnow, B. A., Blasey, C., Manber, R., Constantino, M. J., Markowitz, J. C., Klein, D. N. et al. (2007). Dropouts versus completers among chronically depressed outpatients. Journal of Affective Disorders, 97, 197-202. (Pubitemid 44937434)
5. Arnow, B. A. & Constantino, M.J. (2003). Effectiveness of psychotherapy and combination treatment for chronic depression. Journal of Clinical Psychology, 59, 893-905. (Pubitemid 36897395)
6. Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M. et al. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World Journal of Biological Psychiatry, 8, 67-104. (Pubitemid 46690921)
7. Berlim, M.T., Fleck, M.P. & Turecki, G. (2008). Current trends in the assessment and somatic treatment of resistant/refractory major depression: An overview. Annals of Medicine, 40, 149-159.
8. Crossley, N. A. & Bauer, M. (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry, 68, 935-940.
9. Dodd, S., Horgan, D., Malhi, G. S. & Berk, M. (2005). To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders, 89, 1-11. (Pubitemid 41740829)
10. Dunner, D.L. (2001). Acute and maintenance treatment of chronic depression. Journal of Clinical Psychiatry, 62(Suppl. 6), 10-16. (Pubitemid 32298432)
11. Elkin, I., Shea, M.T., Watkins, J.T., Imber, S. D., Sotsky, S. M., Collins, J. F. et al. (1989). National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Archives of General Psychiatry, 46, 971-982. (Pubitemid 19278225)
12. Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biological Psychiatry, 53, 649-659.
13. Frank, E., Kupfer, D. J., Perel, J. M., Cornes, C., Jarrett, D. B., Mallinger, A. G. et al. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093-1099.
14. Gilmer,W.S.,Trivedi,M. H.,Rush,A. J.,Wisniewski, S. R., Luther, J., Howland, R.H. et al. (2005). Factors associated with chronic depressive episodes:Apreliminary report fromthe STAR-Dproject. Acta Psychiatrica Scandinavica, 112, 425-433. (Pubitemid 41676686)
15. Helbig-Lang, S. & Petermann, F. (2009). Zum empirischen Aussagegehalt des Konzepts «Chronische Depression». Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 57, 235-243.
16. Henkel, V., Seemüller, F., Obermeier, M., Adli, M., Bauer, M., Mundt, C. et al. (2009). Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Journal of Affective Disorders, 115, 439-449.
17. Holsboer, F. (2008). How can we realize the promise of personalized antidepressant medicines? Nature reviews. Neuroscience, 9, 638-646.
18. Jäger, M., Sobocki, P. & Rössler, W. (2008). Cost of disorders of the brain in Switzerland. Swiss Medical Weekly, 138, 4-11.
19. Judd, L. L. & Akiskal, H. S. (2000). Delineating the longitudinal structure of depressive illness: Beyond clinical subtypes and duration thresholds. Pharmacopsychiatry, 33, 3-7.
20. Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W. et al. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry, 55, 694-700. (Pubitemid 28364385)
21. Keller, M.B. (2005). Issues in treatment-resistant depression. Journal of Clinical Psychiatry, 66(Suppl. 8), 5-12.
22. Keller,M. B., Harrison,W., Fawcett, J. A., Gelenberg, A., Hirschfeld, R. M., Klein, D. et al. (1995) Treatment of chronic depression with sertraline or imipramine: Preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacology Bulletin, 31, 205-212.
23. Kennedy, N., Abbott, R. & Paykel, E. S. (2003). Remission and recurrence of depression in the maintenance era: Long-term outcome in a Cambridge cohort. Psychological Medicine, 33, 827-838. (Pubitemid 36874662)
24. Klein, D. N., Shankman, S. A. & Rose, S. (2006). Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. American Journal of Psychiatry, 163, 872-880.
25. Klerman, G. L., Weissman, M. M., Rounsaville, B. J. & Chevron, E. S. (1984). Interpersonal psychotherapy of depression. New York: Basic Books.
26. Kocsis, J. H., Gelenberg, A. J., Rothbaum, B., Klein, D. N., Trivedi, M.H., Manber, R. et al. (2008). Chronic forms of major depression are still undertreated in the 21st century: Systematic assessment of 801 patients presenting for treatment. Journal of Affective Disorders, 110, 55-61.
27. Kocsis, J. H., Rush, A. J., Markowitz, J. C., Borian, F. E., Dunner, D. L., Koran, L. M. et al. (2003). Continuation treatment of chronic depression: A comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacology Bulletin, 37, 73-87.
28. Ley, P., Helbig-Lang, S.&Petermann, F. (2009). Kann man chronische Depression effektiv psychotherapeutisch behandeln? Evidenzbasierung psychotherapeutischer Ansätze. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 57, 253-263.
29. Markowitz, J.C. (1998). Interpersonal psychotherapy for dysthymic disorder.Washington, DC: American Psychiatric Press.
30. McCullough, J. P. (2000). Treatment for chronic depression: Cognitive Behavioral Analysis System of Psychotherapy. New York: Guilford.
31. McCullough, J. P. (2003). Treatment for chronic depression using Cognitive Behavioral Analysis System of Psychotherapy (CBASP). Journal of Clinical Psychology, 59, 833-846. (Pubitemid 36897390)
32. McCullough, J. P. (2006). Psychotherapie der chronischen Depression. Cognitive Behavioral Analysis System of Psychotherapy - CBASP. München: Urban und Fischer.
33. McCullough, J. P., Klein, D. N., Borian, F. E., Howland, R. H., Riso, L. P., Keller, M. B. & Banks, P. L. (2003). Group comparisons of DSM-IV subtypes of chronic depression: Validity of the distinctions, part 2. Journal of Abnormal Psychology, 112, 614-622.
34. Montgomery, S. A. (2002). Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. International Clinical Psychopharmacology, 17(Suppl. 4), 9-15.
35. Nemeroff, C. B. (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry, 68 (Suppl. 8), 17-25.
36. Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M.E., McGrath, P. J. et al. (2006). A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. American Journal of Psychiatry, 163, 1519-1530. (Pubitemid 44465751)
37. Papakostas, G. I., Shelton, R.C., Smith, J. & Fava,M. (2007). Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: A metaanalysis. Journal of Clinical Psychiatry, 68, 826-831. (Pubitemid 47015480)
38. Parker, G.B., Malhi, G.S., Crawford, J.G. & Thase, M.E. (2005). Identifying «paradigm failures» contributing to treatment-resistant depression. Journal of Affective Disorders, 87, 185-191.
39. Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J. & Barocka, A. (1995). Residual symptoms after partial remission: An important outcome in depression. Psychological Medicine, 225, 1171-1180.
40. Rocca, P., Fonzo, V., Ravizza, L., Rocca, G., Scotta, M., Zanalda, E. & Bogetto, F. (2002). A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. Journal of Affective Disorders, 70, 313-317. (Pubitemid 34786647)
41. Schmauss, M.&Messer, T. (2009). Kombination von Antidepressiva - Eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen? Fortschritte der Neurologie - Psychiatrie, 77, 316-325.
42. Schramm, E., Caspar, F. & Berger, M. (2006). Spezifische Therapie für chronische Depression. Das «Cognitive Behavioral Analysis System of Psychotherapy» nach McCullough. Nervenarzt, 77, 355-371.
43. Schramm, E., van Calker, D., Dykierek, P., Lieb, K., Kech, S., Zobel, I. et al. (2007). An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: Acute and long-term results. American Journal of Psychiatry, 164, 768-777. (Pubitemid 46808532)
44. Schweiger, U., Sipos, V., Rudolf, S., Steinlechner, S. & Hohagen, F. (2007). Psychotherapie bei chronischer Depression. Nervenarzt, 78(Suppl. 3), 565-571.
45. Shelton, R. C. & Papakostas, G. I. (2008). Augmentation of anti-depressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatrica Scandinavica, 117, 253-259. (Pubitemid 351350599)
46. Silva de Lima, M. & Hotopf, M. (2003). Pharmacotherapy for dysthymia. Cochrane Database of Systematic Reviews, 3, CD004047.
47. Silva De Lima, M., Moncrieff, J. & Soares, B. (2005). Drugs versus placebo for dysthymia. Cochrane Database of Systematic Reviews, 2, CD001130.
48. Sobocki, P., Jönsson, B., Angst, J. & Rehnberg, C. (2006). Cost of depression in Europe. Journal of Mental Health Policy and Economics, 9, 87-98.
49. Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P.W., Shea, M.T. et al. (2000). Multiple recurrences of major depressive disorder. American Journal of Psychiatry, 157, 229-233. (Pubitemid 30080902)
50. Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O. et al. (1999). Treatment resistant depression: Methodological overview and operational criteria. European Neuropsychopharmacology, 9, 83-91. (Pubitemid 29073687)
51. Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K. et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. Journal of Clinical Psychiatry, 68, 1062-1070. (Pubitemid 47340327)
52. Torpey, D. C. & Klein, D. N. (2008). Chronic depression: Update on classification and treatment. Current Psychiatry Reports, 10, 458-464.
53. Trivedi, M.H., Fava, M., Wisniewski, S. R., Thase, M.E., Quitkin, F., Warden, D. et al. (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine, 354, 1243-1252.
54. Zanardi, R. & Smeraldi, E. (2006). A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. European Neuropsychopharmacology, 16, 281-287.